Get Psyence Biomedical alerts: Psyence Biomedical (NASDAQ:PBM – Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.51 EPS for the quarter.

Psyence Biomedical Ltd. NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed” or the "Company") today announced that it has entered into definitive agreements for the purchase ...

Psyence Biomedical (PBM) highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psilocybin, in conjunction with psychotherapy, as a potential ...

Psyence Biomedical Ltd. has completed a private placement, raising approximately $2 million by selling 1,000,000 common shares along with series A and series B common warrants, with an exercise ...

Psyence Biomedical Ltd. announced that it has regained compliance with Nasdaq's continued listing requirements, as confirmed by the Nasdaq Hearings panel. Following a transfer to The Nasdaq ...

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt ...